As medical schools wrestle with how to keep drug companies from corrupting their faculties, Stanford University often is lauded for its tough stance. But a ProPublica investigation found that more than a dozen of the school’s doctors were

“We expect that this collaboration will be a critical advantage for Aastrom as we move our cardiovascular programs into the final stages of clinical development,” said Aastrom CEO Tim Mayleben in prepared remarks.

Forty-four percent of the people who took a poll by the Nashville Business Journal think their city’s medical trade center project is key for economic development so it should get state tax credits to draw tenants.

Tim Mayleben had a front-row seat as a board member to the shaky period two years ago when stem cell company Aastrom Biosciences was clinging to survival. Now, he’s in the driver’s seat as things are looking up for the publicly traded biotech firm.In 2012, Aastrom (Nasdaq: ASTM) could launch its first product–a treatment [...]

Aastrom Biosciences Inc. has finished treating patients in a Phase 2 clinical trial of its cardiac-repair stem cells.The milestone clears the way for Aastrom to report six-month interim results of the trial later this year, according to a statement from the company.In the trial, Aastrom treated 40 patients suffering from dilated cardiomyopathy, a severe form [...]

Aastrom Biosciences, once in danger of being deslisted from the Nasdaq, has regained compliance with the stock exchange’s $1 minimum share price requirement.In December, the stem cell company was granted an extension until March 31 from being delisted. The company said its stock would have to trade above $1 for 10 consecutive days [...]

Stem cell company Aastrom Biosciences plans to begin a Phase 3 clinical trial of its treatment for critical limb ischemia.Critical limb ischemia results from a decreased blood supply, is often the endpoint of peripheral arterial disease and can lead to amputation.Aastrom said it will proceed with the Phase 3 trial of its vascular repair cells [...]

Aastrom Biosciences Inc. has completed a 1-for-8 reverse stock split that has so far achieved its desired effect–pushing the company’s share price above $1 so it can remain listed on the Nasdaq stock exchange.

Stem cell company Aastrom Biosciences announced an 8-for-1 reverse stock split in an attempt to avoid being delisted by the Nasdaq stock exchange.

Aastrom, which is developing therapies that use stem cells to treat cardiovascular diseases, priced its shares at 26 cents per unit and hopes to raise $10.9 million from the offering.